Motus GI Holdings Inc (NASDAQ:MOTS) Short Interest Update

Motus GI Holdings Inc (NASDAQ:MOTS) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 800,300 shares, a growth of 28.7% from the May 30th total of 621,900 shares. Approximately 5.6% of the company’s shares are sold short. Based on an average daily volume of 137,700 shares, the days-to-cover ratio is currently 5.8 days.

MOTS stock traded down $0.02 during mid-day trading on Friday, reaching $3.13. The company had a trading volume of 399,554 shares, compared to its average volume of 256,392. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.36 and a quick ratio of 6.31. The stock has a market cap of $67.57 million, a P/E ratio of -2.54 and a beta of 1.61. The business has a 50 day moving average of $3.41. Motus GI has a 12 month low of $2.34 and a 12 month high of $8.48.

Motus GI (NASDAQ:MOTS) last issued its earnings results on Friday, May 10th. The company reported ($0.29) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.29). Equities analysts anticipate that Motus GI will post -1.14 EPS for the current fiscal year.

A number of analysts recently weighed in on MOTS shares. Piper Jaffray Companies reduced their price objective on shares of Motus GI from $8.00 to $6.00 in a research report on Friday, May 10th. Oppenheimer set a $10.00 price objective on shares of Motus GI and gave the stock a “buy” rating in a research report on Thursday, March 28th. Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $8.60.

In other news, major shareholder Larry N. Feinberg acquired 1,031,666 shares of Motus GI stock in a transaction that occurred on Monday, July 1st. The shares were bought at an average cost of $3.00 per share, with a total value of $3,094,998.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 1,000,000 shares of Motus GI stock in a transaction that occurred on Thursday, June 27th. The stock was purchased at an average cost of $3.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 2,059,332 shares of company stock worth $6,179,896 over the last three months. 18.14% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of MOTS. Spark Investment Management LLC grew its stake in Motus GI by 73.5% in the 1st quarter. Spark Investment Management LLC now owns 28,900 shares of the company’s stock worth $112,000 after acquiring an additional 12,245 shares in the last quarter. Maven Securities LTD bought a new position in shares of Motus GI during the fourth quarter valued at approximately $167,000. Mesirow Financial Investment Management Inc. bought a new position in shares of Motus GI during the first quarter valued at approximately $350,000. RTW Investments LP boosted its stake in shares of Motus GI by 672.5% during the fourth quarter. RTW Investments LP now owns 459,478 shares of the company’s stock valued at $1,429,000 after purchasing an additional 400,000 shares in the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of Motus GI during the fourth quarter valued at approximately $1,555,000. Institutional investors and hedge funds own 35.30% of the company’s stock.

Motus GI Company Profile

Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

Further Reading: How to invest in blue-chip stocks

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.